Skip to main content

Table 3 RECIST 1.1 response classification at 3 months post-treatment

From: Mode of progression after radioembolization in patients with colorectal cancer liver metastases

Total No extrahepatic metastases at baseline   48(53%)
  Complete response
Partial response
Stable disease
Progressive disease
0 (0%)
5 (10%)
13 (27%)
30 (63%)
  Extrahepatic metastases at baseline   42 (47%)
  Complete response
Partial response
Stable disease
Progressive disease
0 (0%)
0 (0%)
3 (7%)
39 (93%)*
Yttrium-90 Resin No extrahepatic metastases at baseline   28(61%)
  Complete response
Partial response
Stable disease
Progressive disease
0 (0%)
1 (4%)
7 (25%)
20 (71%)
  Extrahepatic metastases at baseline   18 (39%)
  Complete response
Partial response
Stable disease
Progressive disease
0 (0%)
0 (0%)
2 (11%)
16 (89%)
Yttrium-90 Glass No extrahepatic metastases at baseline   9 (45%)
  Complete response
Partial response
Stable disease
Progressive disease
0 (0%)
2 (22%)
2 (22%)
5 (56%)
  Extrahepatic metastases at baseline   11 (55%)
  Complete response
Partial response
Stable disease
Progressive disease
0 (0%)
0 (0%)
0 (0%)
11 (100%)
Holmium-166 No extrahepatic metastases at baseline   11 (46%)
  Complete response
Partial response
Stable disease
Progressive disease
0 (0%)
2 (18%)
4 (36%)
5 (46%)
  Extrahepatic metastases at baseline   13 (54%)
  Complete response
Partial response
Stable disease
Progressive disease
0 (0%)
0 (0%)
1 (8%)
12 (92%) *
  1. This table shows a comparison of RECIST 1.1 response classification at 3 months post-treatment for patients with or without extrahepatic metastases at baseline. Numbers represent number of patients (% of total/subcategory)
  2. *Marks significant difference between groups; p < 0.05